SCHEMBL4283517

SCHEMBL4283517

CNCC(=O)Nc1cc(N2CCOCC2)ccc1C(=O)Nc1[nH]nc2c1CN(S(=O)(=O)c1cc(F)cc(F)c1)C2(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.41
NTRK3 Q16288 4/20 0.41
NTRK2 Q16620 4/20 0.41
IGF1R P08069 9/20 0.41
ALK Q9UM73 13/20 0.39
INSR P06213 12/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
PRKCG P05129 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
LYN P07948 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
ROS1 P08922 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282616 0.88 NTRK1 (0.55) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL4285178 0.80 IGF1R (0.60) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL4285299 0.80 NTRK1 (0.55) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL4285425 0.79 NTRK1 (0.54) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL1890993 0.76 ALK (0.48) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL12640394 0.76 NTRK1 (0.55) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL4105665 0.76 IGF1R (0.43) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL1373571 0.75 NTRK1 (0.53) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL1895522 0.75 IGF1R (0.44) NTRK1NTRK3NTRK2IGF1RALK
SCHEMBL1373969 0.74 NTRK1 (0.54) NTRK1NTRK3NTRK2IGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 NTRK1 1106/4885NTRK3 892/4885NTRK2 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.